Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Recombinant Zoster Vaccine LYB004 in Adults
NCT06874842Phase 1Recruiting
- Sponsor
- Patronus Biotech
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of LYB004 in herpes zoster (HZ) (6 arms), sponsored by Patronus Biotech. Primary endpoints: Occurrence of immediate adverse events at 30 minutes, Incidence of solicited AE at 14 days and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
LYB004
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06874842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06874842.